Table 1 List of lncRNAs associated with different cancers

ANRIL

3.9 kb, Multiple isoforms

9q21.3

Regulates CDKN2A/2B locus by recruiting PRC1/PRC2

Oncogenic

Prostate cancer, Leukemia, other diseases

[26, 137–140]

anti-NOS2A

1.9 kb

17q23.2

Down regulates Nos2A

Oncogenic

Meningomas and Glioblastomas

[233]

lncRNA-ATB

2.4 kb

14q11.2

Activated by TGF-β

Oncogenic

Hepatocellular carcinoma

[310]

BC200

0.2 kb

2p21

Translational modulator

Oncogenic

Multiple cancers

[283]

CCAT1

2.6 kb, 5.2 kb

8q.24

Regulates Myc by long range chromatin loops

Oncogenic

Colorectal, gall bladder cancer

[66, 316, 317]

CCAT2

0.34 kb

8q24.21

Involved in Microsatellite stability

Oncogenic

Colorectal, lung, breast cancers

[305, 306, 318]

CRNDE

10.3 kb, Multiple transcripts

16q12.2

Interacts with PRC2, CoREST, regulated by Insulin, IGF

Oncogenic

Colorectal cancer, glioma

[284, 285]

CUDR

2.2 kb

19p13.12

Involved in drug resistance

Oncogenic

Lung, cervical, colon and Bladder cancer

[261, 262]

H19

2.3 kb

11p15.5

Imprinting

Oncogenic

Liver, esophagal, breast, bladder, Pancreatic, colorectal, gastric, cervical

[84–86, 106–127]

HEIH

1.6 kb

5q34.3

Represses PRC2 target genes through EZH2

Oncogenic

Hepatocellular carcinoma

[225]

HOTAIR

2.2 kb

12q13.13

Chromatin modification by binding to PRC2, LSD1

Oncogeneic

Breast, liver, lung, gastrointestinal and colorectal

[160–171]

HULC

0.5 kb

6p24.3

Interactor of CREB

Oncogenic

Hepatocellular carcinoma

[220–224]

KCNQ1OT1

91.5 kb

11p15.5

Imprinted lncRNA, binds to PRC2 & G9a

Oncogenic

Colorectal cancer

[82, 83, 128–135]

MALAT1

~8 kb

11q13.1

Modulates alternative splicing

Oncogenic

Colorectal and breast cancers

[29, 67, 176–189]

NEAT1

3.7 kb, 23 kb

11q13.1

Transcriptional and Post transcriptional regulation

Oncogenic

Prostate cancer and leukemias

[34, 174, 175]

ncRAN/ SNHG16

2 kb

17q25.1

Interacts with N-myc

Oncogenic

Bladder, colorectal cancer, neuroblastoma

[286, 287]

PCA3

0.6, 2 kb, 4 kb and 23 kb

9q21.2

AR signaling

Oncogenic

Prostae Cancer

[226, 227, 257]

PCAT1

7.8 kb

8q24.21

Inhibits homologous recombination

Oncogenic

Prostate cancer

[230, 231]

PCGEM

27 kb

2q32

Activates AR regulated genes

Oncogenic

Prostate cancer

[228, 229]

PCNA-AS1

384 bp

20p12.3

Increases stability of PCNA mRNA

oncogenic

Hepatocellular carcinoma

[311]

PlncRNA-1

24.5

21q22.12

Interacts with AR

Oncogenic

Prostate cancer

[259]

PRNCR1

13 kb

8q24.22

Activates AR regulated genes

Oncogenic

Prostate cancer

[288]

PVT1

>300 kb, Mutiple transcripts

8q24

Interacts with p53

Oncogenic

Liver, breast, ovarian, colorectal, gastric, nonsmall cell lung cancer and leukemia

[289–295]

SChLAP1/ PCAT114

224.8 kb

2q31.3

Inhibits binding of SWI/SNF on genome

Oncogenic

Prostate cancer

[296]

SRA

2 kb

5q31.3

Regulation through steroid hormones and PRC2

Oncogenic

Prostate, breast, ovarian and uterine cancers

[69, 98, 190–195]

TUG1

6.7 kb, splice variants

22q12.2

Interacts with PRC2 to repress target genes, induced by p53

Oncogenic

Urothelial and non small cell lung cancer

[297, 298]

UCA1

1.4 kb, 2.2 kb, 2.7 kb

19p13.12

Regulates cell cycle through CREB

Oncogenic

Bladder and Breast cancer

[312–315]

AK126698

3.8 kb

1q24.2.

Cisplatin resistance through Wnt signaling

Tumor Suppressor

Non-small cell lung cancer

[299]

BANCR

693 bp

9q21.11

Regulates MAPK pathway

Tumor suppressor

Melanoma, retinoblastoma, lung

[307–309]

GAS5/ SNHG2

Multiple lnc and snoRNAs

1q25.1

Hormonal regulation (GR)

Tumor Suppressor

Breast, prostste, Gastric, cervical and renal cell cancers

[22, 196–205]

LET

2.6 kb

15q24.1

Repression by HDAC3 under hypoxia conditions

Tumor Suppressor

Lung, liver and colorectal cancer

[300]

LincRNA-p21

3 kb

6p21.2/ NA?

p53 dependent repression of genes through hnRNP-K

Tumor suppressor

Lymphoma, lung, colorectal carcinomas

[28, 55, 56, 280]

MEG3

1.6 kb, splicing isoforms

14q32.2

Positive regulator of p53

Tumor suppressor

Prostate, bladder, Pituitory adenocarcinomas, meningoma

[301–304]

PTEN-P1 (Pseudogene)

~4 kb

9p13.3

Enhances PTEN expression

Tumor suppressor

Prostate, colon cancers

[278]

XIST

19 kb

Xq13.2

Imprinting, binds to PRC2

Tumor suppressor

Breast, ovarian and cervical cancers

[72–76, 141–159]